The activity of inhibitors of dihydrofolate reductase (such as methotrexate) as cancer chemotherapeutic agents has led to the search for alternate target enzyme within the folate pathways that are essential for proliferating cells. Folylpolyglutamate synthetase has these characteristics and is being examined as a new target for folate antimetabolites. Previous studies have indicated that interaction of the glutamic acid side chain of the folate molecule is essential for binding of folate analogs bind poorly to folylpolyglutamate synthetase, a fact that indicates rigid structural requirements in the active site of this enzyme. One class of compounds, however, that are modified in the Omega-position have been found to be the first specific inhibitors of this enzyme. The overall goals of this work are to exploit this lead for the procurement of a potent inhibitor of folylpolyglutamate synthetase in tumor cells. Several new classes of folate analogs will be synthesized. The side chains of these compounds will differ from glutamic acid by modifications that will allow the testing of a number of hypotheses related to interactions between substrates and enzyme. We would modify the folate structure so as to : 1) alter the pKa of the Alpha- or Gamma-carboxyls; 2) allow the alkylation of any basic amino acid interacting with the Alpha-carboxyl of the folate substrate; 3) increase the binding of homocysteic acid analogs to enzymes; 4) replace the Alpha- or Gamma-carbosyls with other charged moieties; and 5) eliminate the Alpha- or Gamma-carboxyl in any analog that bound tightly to enzyme. These compounds will be studied as inhibitors of polyglutamation using partially purified mammalian folylpolyglutamate synthetase and also in intact mammalian tumor cells in culture. A compound that inhibits this process will be used to select for resistant cell lines. The cytotoxicity of new analogs will be tested against tumor cells in culture and in vivo.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA039687-01
Application #
3178997
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
1985-09-30
Project End
1988-07-31
Budget Start
1985-09-30
Budget End
1986-09-29
Support Year
1
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Children's Hospital of Los Angeles
Department
Type
DUNS #
094878337
City
Los Angeles
State
CA
Country
United States
Zip Code
90027
Yang, Chen; Xie, Lin-Ying; Windle, Jolene J et al. (2014) Humanizing mouse folate metabolism: conversion of the dual-promoter mouse folylpolyglutamate synthetase gene to the human single-promoter structure. FASEB J 28:1998-2008
Lawrence, Scott A; Titus, Steven A; Ferguson, Jennifer et al. (2014) Mammalian mitochondrial and cytosolic folylpolyglutamate synthetase maintain the subcellular compartmentalization of folates. J Biol Chem 289:29386-96
Bareford, M Danielle; Park, Margaret A; Yacoub, Adly et al. (2011) Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res 71:4955-67
Bareford, M Danielle; Hamed, Hossein A; Tang, Yong et al. (2011) Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Autophagy 7:1261-2
Racanelli, Alexandra C; Turner, Fiona B; Xie, Lin-Ying et al. (2008) A mouse gene that coordinates epigenetic controls and transcriptional interference to achieve tissue-specific expression. Mol Cell Biol 28:836-48
Tomsho, John W; Moran, Richard G; Coward, James K (2008) Concentration-dependent processivity of multiple glutamate ligations catalyzed by folylpoly-gamma-glutamate synthetase. Biochemistry 47:9040-50
Chattopadhyay, Shrikanta; Moran, Richard G; Goldman, I David (2007) Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 6:404-17
Andreassi 2nd, John L; Moran, Richard G (2002) Mouse folylpoly-gamma-glutamate synthetase isoforms respond differently to feedback inhibition by folylpolyglutamate cofactors. Biochemistry 41:226-35
Turner, F B; Taylor, S M; Moran, R G (2000) Expression patterns of the multiple transcripts from the folylpolyglutamate synthetase gene in human leukemias and normal differentiated tissues. J Biol Chem 275:35960-8
Zhao, R; Titus, S; Gao, F et al. (2000) Molecular analysis of murine leukemia cell lines resistant to 5, 10-dideazatetrahydrofolate identifies several amino acids critical to the function of folylpolyglutamate synthetase. J Biol Chem 275:26599-606

Showing the most recent 10 out of 18 publications